Applying insights from biofilm biology to drug development - can a new approach be developed?

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Applying insights from biofilm biology to drug development - can a new approach be developed? / Bjarnsholt, Thomas; Ciofu, Oana; Molin, Søren; Givskov, Michael; Høiby, Niels.

In: Nature Reviews. Drug Discovery, Vol. 12, No. 10, 01.10.2013, p. 791-808.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Bjarnsholt, T, Ciofu, O, Molin, S, Givskov, M & Høiby, N 2013, 'Applying insights from biofilm biology to drug development - can a new approach be developed?', Nature Reviews. Drug Discovery, vol. 12, no. 10, pp. 791-808. https://doi.org/10.1038/nrd4000

APA

Bjarnsholt, T., Ciofu, O., Molin, S., Givskov, M., & Høiby, N. (2013). Applying insights from biofilm biology to drug development - can a new approach be developed? Nature Reviews. Drug Discovery, 12(10), 791-808. https://doi.org/10.1038/nrd4000

Vancouver

Bjarnsholt T, Ciofu O, Molin S, Givskov M, Høiby N. Applying insights from biofilm biology to drug development - can a new approach be developed? Nature Reviews. Drug Discovery. 2013 Oct 1;12(10):791-808. https://doi.org/10.1038/nrd4000

Author

Bjarnsholt, Thomas ; Ciofu, Oana ; Molin, Søren ; Givskov, Michael ; Høiby, Niels. / Applying insights from biofilm biology to drug development - can a new approach be developed?. In: Nature Reviews. Drug Discovery. 2013 ; Vol. 12, No. 10. pp. 791-808.

Bibtex

@article{9481b89f1d9a4a2dbe883396cf24fd7f,
title = "Applying insights from biofilm biology to drug development - can a new approach be developed?",
abstract = "Most of the research on bacterial pathogenesis has focused on acute infections, but much less is known about the pathogenesis of infections caused by bacteria that grow as aggregates in biofilms. These infections tend to be chronic as they resist innate and adaptive immune defence mechanisms as well as antibiotics, and the treatment of biofilm infections presents a considerable unmet clinical need. To date, there are no drugs that specifically target bacteria in biofilms; however, several approaches are in early-stage development. Here, we review current insights into biofilm physiology and pathology, and discuss how a deep insight into the physical and biological characteristics of biofilms can inform therapeutic strategies and molecular targets for the development of anti-biofilm drugs.",
author = "Thomas Bjarnsholt and Oana Ciofu and S{\o}ren Molin and Michael Givskov and Niels H{\o}iby",
year = "2013",
month = oct,
day = "1",
doi = "10.1038/nrd4000",
language = "English",
volume = "12",
pages = "791--808",
journal = "Nature Reviews. Drug Discovery",
issn = "1474-1776",
publisher = "nature publishing group",
number = "10",

}

RIS

TY - JOUR

T1 - Applying insights from biofilm biology to drug development - can a new approach be developed?

AU - Bjarnsholt, Thomas

AU - Ciofu, Oana

AU - Molin, Søren

AU - Givskov, Michael

AU - Høiby, Niels

PY - 2013/10/1

Y1 - 2013/10/1

N2 - Most of the research on bacterial pathogenesis has focused on acute infections, but much less is known about the pathogenesis of infections caused by bacteria that grow as aggregates in biofilms. These infections tend to be chronic as they resist innate and adaptive immune defence mechanisms as well as antibiotics, and the treatment of biofilm infections presents a considerable unmet clinical need. To date, there are no drugs that specifically target bacteria in biofilms; however, several approaches are in early-stage development. Here, we review current insights into biofilm physiology and pathology, and discuss how a deep insight into the physical and biological characteristics of biofilms can inform therapeutic strategies and molecular targets for the development of anti-biofilm drugs.

AB - Most of the research on bacterial pathogenesis has focused on acute infections, but much less is known about the pathogenesis of infections caused by bacteria that grow as aggregates in biofilms. These infections tend to be chronic as they resist innate and adaptive immune defence mechanisms as well as antibiotics, and the treatment of biofilm infections presents a considerable unmet clinical need. To date, there are no drugs that specifically target bacteria in biofilms; however, several approaches are in early-stage development. Here, we review current insights into biofilm physiology and pathology, and discuss how a deep insight into the physical and biological characteristics of biofilms can inform therapeutic strategies and molecular targets for the development of anti-biofilm drugs.

U2 - 10.1038/nrd4000

DO - 10.1038/nrd4000

M3 - Journal article

C2 - 24080700

VL - 12

SP - 791

EP - 808

JO - Nature Reviews. Drug Discovery

JF - Nature Reviews. Drug Discovery

SN - 1474-1776

IS - 10

ER -

ID: 62354566